Clinical epidemiologist, Washington University in St. Louis
Appears in 2 stories
Active researcher studying GLP-1 benefits and risks
More than 30 million Americans now take GLP-1 receptor agonist drugs like Ozempic and Wegovy to lose weight. A persistent concern has dogged the medications since their rise: that they burn through muscle along with fat, leaving patients weaker even as they get thinner.
Updated May 30
Lead author of the March 2026 BMJ study
Drugs designed to control blood sugar and shrink waistlines may also quiet the cravings that drive addiction. A March 4 BMJ study of more than 600,000 U.S. veterans found GLP-1 users were 14 percent less likely to develop a new substance use disorder.
No stories match your search
Try a different keyword
How would you like to describe your experience with the app today?
